Features Screener Stocks Charts
Sign In Sign Up

Strides Arcolab Ltd. Cash Flow Statement

NSE:STAR | PHARMACEUTICALS

Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.

View Plans

Cash Flow Insights

Cash Conversion

0.19x

STAR's operating cash flow was significantly below net income in FY 2025, suggesting earnings include substantial non-cash items.

Free Cash Flow

₹4.42B

STAR's free cash flow was ₹4.42B in FY 2025, down 24.2% from FY 2024.

Dividend Coverage

19.2x

STAR's free cash flow covered dividends 19.2x in FY 2025, leaving room for reinvestment or debt reduction.

CapEx Intensity

35.4%

Capital expenditure was 35.4% of operating cash flow in FY 2025 for STAR, a moderate level of reinvestment.

2-year STAR cash flow snapshot

Hover the chart icon for YoY change.

FY 2024 - FY 2025
Item Chart 2024 2025
Net Income -627.22M 36.75B
Cash flow Operating Activities 7.01B 6.84B
Investments in PPE -1.18B -2.42B
Cash flow Investing Activities -1.50B -896.89M
Dividend Paid -135.17M -229.90M
Cash flow Financing Activities -6.93B -6.43B
Cash at beginning of period 3.04B 1.61B
Cash at end of period 1.61B 1.13B
Free Cash Flow 5.83B 4.42B

Values are shown in millions (M) and billions (B). All amounts are in Indian Rupees (₹).

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025